Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI-102 and Pasritamig in Metastatic Castration-resistant Prostate Cancer (JET-201)
NCT07871435Phase 2Recruiting
- Sponsor
- GI Innovation
- Start
- Oct 2026
- Primary completion
- Mar 2029
- Countries
- 2
01
Overview
A Phase 2 trial of GI-101A in metastatic castration-resistant prostate cancer (mCRPC), sponsored by GI Innovation. Started Oct 2026; status: recruiting.
02
Drugs
GI-101A
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07871435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07871435.